Literature DB >> 23104188

HCT for nonmalignant disorders.

John F Tisdale1, Mary Eapen, Riccardo Saccardi.   

Abstract

Mesh：

Year:  2012        PMID： 23104188     DOI： 10.1016/j.bbmt.2012.10.007

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


× No keyword cloud information.
  4 in total

1.  Posttransplant cyclophosphamide in allogeneic bone marrow transplantation for the treatment of nonmalignant hematological diseases.

Authors:  Mark Leick; Bradley Hunter; Zachariah DeFilipp; Bimalangshu R Dey; Areej El-Jawahri; Matthew Frigault; Steven McAfee; Thomas R Spitzer; Paul O'Donnell; Yi-Bin Chen
Journal:  Bone Marrow Transplant       Date:  2019-10-24       Impact factor: 5.483

2.  Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide.

Authors:  Amy E DeZern; Marianna L Zahurak; Heather J Symons; Kenneth R Cooke; Gary L Rosner; Douglas E Gladstone; Carol Ann Huff; Lode J Swinnen; Philip Imus; Ivan Borrello; Nina Wagner-Johnston; Richard F Ambinder; Leo Luznik; Javier Bolaños-Meade; Ephraim J Fuchs; Richard J Jones; Robert A Brodsky
Journal:  Blood Adv       Date:  2020-04-28

3.  Alternative Donor Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Refractory Severe Aplastic Anemia.

Authors:  Amy E DeZern; Marianna Zahurak; Heather Symons; Kenneth Cooke; Richard J Jones; Robert A Brodsky
Journal:  Biol Blood Marrow Transplant       Date:  2016-12-21       Impact factor: 5.742

Review 4.  Haploidentical Donor Bone Marrow Transplantation for Severe Aplastic Anemia.

Authors:  Amy E DeZern; Robert A Brodsky
Journal:  Hematol Oncol Clin North Am       Date:  2018-05-28       Impact factor: 3.722
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.